These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 16239380

  • 1. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract] [Full Text] [Related]

  • 2. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ.
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract] [Full Text] [Related]

  • 3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, Keystone EC, Schiff MH, van Riel PL, Weinblatt ME, Weisman MH.
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
    [No Abstract] [Full Text] [Related]

  • 4. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, Emery P.
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [Abstract] [Full Text] [Related]

  • 5. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
    Brandt J, Sieper J, Braun J.
    Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL, Gause A.
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J.
    Scand J Rheumatol; 2006 Jun; 35(3):182-8. PubMed ID: 16766364
    [Abstract] [Full Text] [Related]

  • 13. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
    Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i2-45. PubMed ID: 22460137
    [No Abstract] [Full Text] [Related]

  • 14. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S.
    Reumatismo; 2009 Apr; 61(2):132-9. PubMed ID: 19633800
    [Abstract] [Full Text] [Related]

  • 15. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
    Kary S, Burmester GR.
    Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
    [Abstract] [Full Text] [Related]

  • 16. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol.
    Langer HE, Missler-Karger B.
    Int J Clin Pharmacol Res; 2003 Apr; 23(4):119-28. PubMed ID: 15224501
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.